{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:15:48Z","timestamp":1785777348029,"version":"3.56.0"},"reference-count":57,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["mAbs"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/19420862.2021.1979447","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T09:36:16Z","timestamp":1639992976000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Development of a nonhuman primate challenge model to evaluate CD8\n            <sup>+<\/sup>\n            T cell responses to an adenovirus-based vaccine expressing SIV proteins upon repeat-dose treatment with checkpoint inhibitors"],"prefix":"10.1080","volume":"14","author":[{"given":"Richard","family":"Graveline","sequence":"first","affiliation":[{"name":"Immunology, Charles River Laboratories, Senneville, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morad","family":"Haida","sequence":"additional","affiliation":[{"name":"Immunology, Charles River Laboratories, Senneville, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyne","family":"Dumont","sequence":"additional","affiliation":[{"name":"Immunology, Charles River Laboratories, Senneville, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Poulin","sequence":"additional","affiliation":[{"name":"Immunology, Charles River Laboratories, Senneville, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Poitout-Belissent","sequence":"additional","affiliation":[{"name":"Immunology, Charles River Laboratories, Senneville, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Samadfam","sequence":"additional","affiliation":[{"name":"Immunology, Charles River Laboratories, Senneville, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Kronenberg","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Regenass-Lechner","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Prell","sequence":"additional","affiliation":[{"name":"Safety Assessment, Development Sciences, Genentech, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Soleil","family":"Piche","sequence":"additional","affiliation":[{"name":"Immunology, Charles River Laboratories, Senneville, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.02.055"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012"},{"key":"e_1_3_2_5_1","first-page":"10","article-title":"Cancer immunotherapy \u2013 revisited","author":"Lesterhuis WJ","year":"2011","unstructured":"Lesterhuis WJ, Haanen JBAG, and Punt CJA. Cancer immunotherapy \u2013 revisited. Nat Rev Drug Discov. 2011;10(8):591-600.","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_3_2_6_1","first-page":"12","article-title":"The blockade of immune checkpoints in cancer immunotherapy","author":"Pardoll DM","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-64.","journal-title":"Nat Rev Cancer"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-017-0184-3"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2014.02.008"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0044"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ilar\/ily014"},{"key":"e_1_3_2_11_1","first-page":"7","article-title":"The oncopig cancer model: an innovative large animal translational oncology platform","author":"Schachtschneider KM","year":"2017","unstructured":"Schachtschneider KM, Schwind RM, Newson J, Kinachtchouk N, Rizko M, Mendoza-Elias N, Grippo P, Principe DR, Park A, and Overgaard NH, et al. The oncopig cancer model: an innovative large animal translational oncology platform. Front Oncol. 2017;7:190.","journal-title":"Front Oncol"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.91"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.10.012"},{"key":"e_1_3_2_14_1","article-title":"Recent advancements and applications of human immune system mice in preclinical immuno-oncology","author":"Curran M","year":"2019","unstructured":"Curran M, Mairesse M, Matas-C\u00e9spedes A, Bareham B, Pellegrini G, Liaunardy A, Powell E, Sargeant R, Cuomo E, and Stebbings R, et al. Recent advancements and applications of human immune system mice in preclinical immuno-oncology. Toxicol Pathol. 2019Feb;48(2):302-316.","journal-title":"Toxicol Pathol"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.07.001"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1111840108"},{"key":"e_1_3_2_17_1","unstructured":"Mak IW Evaniew N Ghert M Review article lost in translation: animal models and clinical trials in cancer treatment [Internet]. 2014. Available from: www.ajtr.org"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw041"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1237-1"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-017-0184-3"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2018.02.003"},{"key":"e_1_3_2_22_1","unstructured":"Messaoudi I Estep R Robinson B Wong SW Nonhuman primate models of human immunology."},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.25234"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000211319.00031.fc"},{"key":"e_1_3_2_25_1","volume-title":"SOT 55th Annual Meeting and ToxExpo","author":"Satterwhite CM","year":"2016","unstructured":"Satterwhite CM, Comba RW, Oldendorp A, and Prell R Investigation of KLH (Keyhole Limpet Hemocyanin) antigen dose response in male and female cynomolgus monkeys to establish an optimal response to study immune enhancement. SOT 55th Annual Meeting and ToxExpo. New Orleans, LA. 2016."},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0040"},{"key":"e_1_3_2_27_1","volume-title":"Journal for ImmunoTherapy of Cancer","author":"Loffredo J","year":"2017","unstructured":"Loffredo J, Vuyyuru R, Spires V, Beyer S, Fox M, Ehrmann J, Taylor K, Engelhardt J, Korman A, and Graziano R Non-fucosylated anti-CTLA-4 antibody enhances vaccine-induced T cell responses in a non-human primate pharmacodynamic vaccine model-32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017). In: Journal for ImmunoTherapy of Cancer. National Harbor, Maryland. 2017."},{"key":"e_1_3_2_28_1","first-page":"171","article-title":"Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques","author":"Keler T","year":"2003","unstructured":"Keler T, Halk E, Vitale L, O\u2019Neill T, Blanset D, Lee S, Srinivasan M, Graziano RF, Davis T, and Lonberg N, et al. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J Immunol. 2003;171(11):6251-9.","journal-title":"J Immunol"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-4703"},{"key":"e_1_3_2_30_1","unstructured":"Macoin J Blein S Monney T Sancheti P Reddy V Back J GBR830 a true OX40 antagonist antibody with potent suppressive effects on T cell-mediated pathological responses [abstract]. In: Arthritis & Rheumatology. American College of Rheumatology; 2018."},{"key":"e_1_3_2_31_1","unstructured":"U. S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761069Orig1s000PharmR.pdf December 2020."},{"key":"e_1_3_2_32_1","unstructured":"European Medicines Agency: EMA assessment report EMA\/CHMP\/392114\/2015 https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/nivolumab-bms-epar-public-assessment-report_en.pdf Access date 01 Dec 2020 ."},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/1547691X.2013.766287"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.2.980"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900317"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1208972109"},{"key":"e_1_3_2_37_1","first-page":"16","article-title":"Transduction properties of adenovirus serotype 35 vectors after intravenous administration into nonhuman primates","author":"Sakurai F","year":"2008","unstructured":"Sakurai F, Nakamura S, Akitomo K, Shibata H, Terao K, Kawabata K, Hayakawa T, and Mizuguchi H. Transduction properties of adenovirus serotype 35 vectors after intravenous administration into nonhuman primates. Mol Ther. 2008;16(4):726-733.","journal-title":"Mol Ther"},{"key":"e_1_3_2_38_1","first-page":"1539","article-title":"Long-term toxicity, pharmacokinetics and immune effects of a recombinant adenovirus vaccine expressing human papillomavirus 16 E6 and E7 proteins (HPV16 E6E7-Ad5 Vac) in primates","volume":"10","author":"Wu J","year":"2018","unstructured":"Wu J, Chen G, Zhuang F-C, Gao M, Wu C-D, He Z-L, Jiang Y-S, Li J-B, Bao J-Y, Mao Z-A. Long-term toxicity, pharmacokinetics and immune effects of a recombinant adenovirus vaccine expressing human papillomavirus 16 E6 and E7 proteins (HPV16 E6E7-Ad5 Vac) in primates. Am J Transl Res. 2018;10:1539\u201351.","journal-title":"Am J Transl Res"},{"key":"e_1_3_2_39_1","first-page":"16","article-title":"Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons","author":"Ni S","year":"2005","unstructured":"Ni S, Bernt K, Gaggar A, Li Z-Y, Kiem H-P, Lieber A. Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum Gene Ther. 2005;16.","journal-title":"Hum Gene Ther"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00716-12"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00199-09"},{"key":"e_1_3_2_42_1","first-page":"7","article-title":"Ex vivo SIV-specific CD8 T cell responses in heterozygous animals are primarily directed against peptides presented by a single MHC haplotype","author":"Greene JM","year":"2012","unstructured":"Greene JM, Chin EN, Budde ML, Lhost JJ, Hines PJ, Burwitz BJ, Broman KW, Nelson JE, Friedrich TC, and O\u2019Connor DH. Ex vivo SIV-specific CD8 T cell responses in heterozygous animals are primarily directed against peptides presented by a single MHC haplotype. Plos One. 2012;7(8):e43690.","journal-title":"Plos One"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02160-08"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2018.05.001"},{"key":"e_1_3_2_45_1","first-page":"10","article-title":"AdHu5Ag85A respiratory mucosal boost immunization enhances protection against pulmonary tuberculosis in bcg-primed non-human primates","author":"Jeyanathan M","year":"2015","unstructured":"Jeyanathan M, Shao Z, Yu X, Harkness R, Jiang R, Li J, Xing Z, and Zhu T. AdHu5Ag85A respiratory mucosal boost immunization enhances protection against pulmonary tuberculosis in bcg-primed non-human primates. Plos One. 2015;10(8):e0135009.","journal-title":"Plos One"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00549-15"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.03.019"},{"key":"e_1_3_2_48_1","first-page":"7","article-title":"Differential expression of immune checkpoint modulators on in vitro primed CD4+ and CD8+ T cells","author":"Sabins NC","year":"2016","unstructured":"Sabins NC, Harman BC, Barone LR, Shen S, and Santulli-Marotto S. Differential expression of immune checkpoint modulators on in vitro primed CD4+ and CD8+ T cells. Front Immunol. 2016;7:221.","journal-title":"Front Immunol"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1806314115"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp500646d"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3300958"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.141"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302017"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.5.733"},{"key":"e_1_3_2_55_1","first-page":"7","article-title":"Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment","author":"Fehlings M","year":"2019","unstructured":"Fehlings M, Jhunjhunwala S, Kowanetz M, O\u2019Gorman WE, Hegde PS, Sumatoh H, Lee BH, Nardin A, Becht E, Flynn S, et al. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. J ImmunoTher Cancer. 2019;7.","journal-title":"J ImmunoTher Cancer"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-CT301"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02355-10"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2011.09.008"}],"container-title":["mAbs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/19420862.2021.1979447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T13:08:26Z","timestamp":1734354506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2021.1979447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/19420862.2021.1979447"],"URL":"https:\/\/doi.org\/10.1080\/19420862.2021.1979447","relation":{},"ISSN":["1942-0862","1942-0870"],"issn-type":[{"value":"1942-0862","type":"print"},{"value":"1942-0870","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1979447"}}